Co-infections and COVID-19


Meet the challenges that this unusual flu season will bring

The arrival of the influenza-like illness season has coincided with another rise in COVID-19 cases, as the pandemic continues across the globe. Check out our article on the top 3 considerations during this unusual flu season.

Read the article

COVID-19 and co-infection – what do we know?

Many tests provide an answer about the presence of SARS-CoV-2. However, a new 30-study systematic review and meta-analysis published in the Journal of Infection suggests that some patients may be infected by more than one pathogen. How can you test for multiple respiratory pathogens when time is of the essence?

Read the study highlights

Learn about the role of multiplex testing in the COVID-19 pandemic

During this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.

Watch the webinar

QIAstat-Dx Respiratory SARS-CoV-2 Panel
(Emergency Use Authorization)

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 21 respiratory targets, including SARS-CoV-2 from Nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Learn more

* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx® Respiratory SARS-CoV-2 Panel.

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
  • This test has not been FDA cleared or approved;
  • This test has been authorized by FDA under an EUA for use by authorized laboratories;
  • This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Social Sharing